Olumiant, or Baricitinib, is an oral drug developed by US biopharmaceutical major, Incyte Corporation, and licensed to Eli Lilly

US pharma giant Eli Lilly has issued royalty-free, non-exclusive voluntary licences to three Indian drug makers – Cipla, Sun Pharmaceuticals and Lupin – to manufacture and distribute Baricitinib, which is being used to treat Covid-19.

Earlier, Gilead too had signed non-exclusive voluntary licensing agreements with Indian pharmaceutical companies to expand the production of Remdesivir, a widely used anti-Covid drug. “The voluntary licensing agreements will ensure high-quality manufacturing and accessibility of Baricitinib during this pandemic, improving the local treatment